RESUMEN
Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma (DTC). From December 2015 to May 2019, 689 patients undergone RRA at Nuclear Medicine Department, Second Hospital of Shandong University were included in the study. Patients were categorized by their pre-ablative TSH level grouping of < 30, 30-70 and ≥ 70 mIU/L. Response to RRA were evaluated as complete response (including excellent and indeterminate response) and incomplete response (including biochemical and structural incomplete response) after a follow-up of 6-8 months. Multivariable binary logistic regression model was used to explore the optimum pre-ablative TSH level range and independent factors associated with response to RRA. Rates of complete response to RRA were 63.04%, 74.59% and 66.41% in TSH level groups of < 30, 30-70 and ≥ 70 mIU/L, separately. With multivariate analysis, the study found that pre-ablative TSH levels, gender and lymph node dissection were independent predictors of response to RRA. TSH between 30 and 70 mIU/L had a higher rate of complete response compared with TSH < 30 mIU/L, OR 0.451 (95% CI 0.215-0.958, P = 0.036). A pre-ablative TSH level of 30-70 mIU/L was appropriate for patients with DTC to achieve a better response to RRA.
Asunto(s)
Radioisótopos de Yodo/administración & dosificación , Neoplasias de la Tiroides/sangre , Neoplasias de la Tiroides/tratamiento farmacológico , Tirotropina/administración & dosificación , Adulto , Femenino , Estudios de Seguimiento , Humanos , Radioisótopos de Yodo/farmacocinética , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Neoplasias de la Tiroides/patología , Tirotropina/farmacocinéticaRESUMEN
PURPOSE: In DTC patients, 131-radioiodine therapy has routinely been used for many years for thyroid remnant ablation after thyroid surgery. To date, two different strategies can be used to achieve sufficient TSH stimulation on thyroid remnant: (I) Levo-thyroxine withdrawal or (II) rhTSH stimulation. The aim of our study was to compare the abdominal absorbed dose ratio between differentiated thyroid cancer patients who underwent thyroid remnant ablation after either L-T4 withdrawal or rhTSH stimulation. METHODS: We reviewed the records of 63 patients affected by differentiated thyroid cancer. All patients underwent thyroid remnant ablation after either L-T4 withdrawal or rhTSH stimulation. A post-therapy whole-body scan was obtained 5 days after 131-radioiodine therapy. Qualitative and quantitative image analysis was performed. Quantitative analysis was performed by drawing seven regions of interest on the abdomen (anterior and posterior views) to estimate both the activity ratio (AR) and absorbed dose ratio (DR) obtained in patients treated in hypothyroidism or after rhTSH stimulation. RESULTS: The values of the activity and absorbed dose ratios obtained on each abdomen region (liver, stomach, ascending colon, transverse colon, descending colon, rectum, and small intestine) were always higher in patients treated after L-T4 withdrawal than after rhTSH stimulation with p-values of 0.000, 0.000, 0.001, 0.000, 0.022, 0.007, and 0.002, respectively. CONCLUSIONS: DTC patients treated with 131-radioiodine after rhTSH stimulation have lower abdominal radioiodine activity than hypothyroid patients. Our data could be of practical relevance in terms of patient management. The potential impact on rare radioiodine-related gastrointestinal side effects is to be established in specifically designed prospective studies.
Asunto(s)
Abdomen/efectos de la radiación , Adenocarcinoma , Radioisótopos de Yodo/uso terapéutico , Neoplasias de la Tiroides , Tirotropina/administración & dosificación , Tiroxina/administración & dosificación , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/metabolismo , Adenocarcinoma/radioterapia , Adenocarcinoma/cirugía , Esquema de Medicación , Femenino , Absorción Gastrointestinal/efectos de la radiación , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Residual , Órganos en Riesgo , Traumatismos por Radiación/etiología , Traumatismos por Radiación/prevención & control , Dosificación Radioterapéutica , Radioterapia Adyuvante , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Estudios Retrospectivos , Neoplasias de la Tiroides/tratamiento farmacológico , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/radioterapia , Neoplasias de la Tiroides/cirugía , Tiroidectomía , Tirotropina/farmacocinética , Tiroxina/farmacocinética , Resultado del Tratamiento , Privación de TratamientoRESUMEN
Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the α-subunit and one in the ß-subunit. These sites are not always occupied and occupancy is frequently neglected in glycoprotein characterization, even though it is related to folding, trafficking, initiation of inflammation and host defense, as well as congenital disorders of glycosylation (CDG). For the first time N-glycoprofiling analysis was applied to the site-occupancy determination of two native pituitary hTSH, in comparison with three recombinant preparations of hTSH, a widely used biopharmaceutical. A single methodology provided the: (i) average N-glycan mass; (ii) mass fraction of each monosaccharide and of sulfate; and (iii) percent carbohydrate. The results indicate that the occupancy (65%-87%) and carbohydrate mass (12%-19%) can be up to 34%-57% higher in recombinant hormones. The average glycan mass is 24% lower in pituitary hTSH and contains ~3-fold fewer moles of galactose (p < 0.005) and sialic acid (p < 0.01). One of the two native preparations, which had the smallest glycan mass together with the lowest occupancy and GalNAc, sulfate, Gal and sialic acid contents, also presented the lowest in vivo bioactivity and circulatory half-life. The methodology described, comparing a recombinant biopharmaceutical to its native equivalent, can be applied to any physiologically or clinical relevant glycoprotein.
Asunto(s)
Carbohidratos/química , Glicoproteínas/química , Glicoproteínas/metabolismo , Tirotropina/química , Tirotropina/metabolismo , Animales , Células CHO , Cricetulus , Glicoproteínas/farmacocinética , Glicosilación , Humanos , Ratones , Polisacáridos , Proteínas Recombinantes , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Tirotropina/farmacocinéticaRESUMEN
AIM: Previous studies listed body surface area (BSA), lean body mass (LBM), and age as modifying factors on the TSH concentrations after administration of recombinant human thyrotropin (rhTSH). The purpose of this study was to identify the main modifying factors on serum TSH levels and to compare the stimulation via single rhTSH injection after a short thyroid hormone withdrawal (THW) with that of the standard stimulating protocol. PATIENTS, METHODS: 106 patients with differentiated thyroid cancer (DTC) undergoing radioiodine therapy (RIT) after rhTSH administration were obtained through chart review. Two groups were evaluated: Group I was treated with a single rhTSH administration after two weeks of T3 therapy followed by one week of THW. Group II was stimulated according to the international standard protocol via rhTSH injections for two consecutive days. Serum TSH concentrations were documented prior to rhTSH administration (day 1 TSH), one day after (day 3 TSH) and 3-6 days after (mean 4.2 days, day 6 TSH) the last rhTSH injection. The following data was collected: age, gender, weight, height, BMI, LBM, BSA, residual thyroid tissue, CRP, creatinine, GFR, liver enzymes, alkaline phosphatase, cholesterol, and triglycerides. RESULTS: Group I: Age combined with anthropometric factors like BMI (TSH increase and day 6 TSH), BSA (TSH decrease), and gender (day 6 TSH) are the main modifying factors on serum TSH concentrations after rhTSH administration. Group II: Age and lean body mass (LBM) showed a significant impact on day 3 TSH, TSH increase (day 3-day 1), and TSH decrease (day 6-day 3). Day 6 TSH was found to be influenced by GFR (group II). CONCLUSION: Age and anthropometric parameters have significant independent influence on TSH concentrations after rhTSH injection in both groups. Anthropometric parameters (BSA, LBM) and demographic parameters (female gender) show strong influence on TSH concentrations. Further research should be conducted to examine the influence of body compartments on TSH levels through measuring total body water.
Asunto(s)
Envejecimiento/sangre , Composición Corporal , Neoplasias de la Tiroides/sangre , Neoplasias de la Tiroides/terapia , Tirotropina/sangre , Tirotropina/farmacocinética , Quimioterapia Adyuvante/métodos , Femenino , Humanos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/sangre , Proteínas Recombinantes/farmacocinética , Caracteres Sexuales , Tirotropina/administración & dosificaciónRESUMEN
Drug malabsorption is a potential concern after bariatric surgery. We present four case reports of hypothyroid patients who were well replaced with thyroxine tablets to euthyroid thyrotropin (TSH) levels prior to Roux-en-Y gastric bypass surgery. These patients developed elevated TSH levels after the surgery, the TSH responded reversibly to switching from treatment with oral tablets to a liquid formulation.
Asunto(s)
Derivación Gástrica , Síndromes de Malabsorción/tratamiento farmacológico , Obesidad Mórbida/metabolismo , Suspensiones , Comprimidos , Tirotropina/farmacocinética , Tiroxina/farmacocinética , Adulto , Femenino , Derivación Gástrica/efectos adversos , Humanos , Persona de Mediana Edad , Obesidad Mórbida/tratamiento farmacológico , Obesidad Mórbida/cirugía , Equivalencia Terapéutica , Resultado del TratamientoRESUMEN
Thyrogen (thyrotropin alfa for injection), recombinant human TSH (rhTSH), has been successfully used to enhance diagnostic radioiodine scanning and thyroglobulin testing in the follow-up of patients with thyroid cancer and as an adjunctive treatment for radioiodine thyroid remnant ablation. However, the short half-life of rhTSH in the circulation requires a multidose regimen. We developed novel sialic acid-mediated and galactose-mediated conjugation chemistries for targeting polyethylene glycol (PEG) to the three N-linked glycosylation sites on the protein, to prolong plasma half-life by eliminating kidney filtration and potential carbohydrate-mediated clearance. Conjugates of different PEG sizes and copy numbers were screened for reaction yield, TSH receptor binding, and murine phamacokinetics/pharmacodynamics studies. The best performing of these products, a 40-kDa mono-PEGylated sialic acid-mediated conjugate, exhibited a 3.5-fold longer duration of action than rhTSH in rats, as a 5-fold lower affinity was more than compensated by a 23-fold extension of circulation half-life. Biochemical characterization confirmed conjugation through the sialic acids. Correlation of PEG distribution on the three N-linked glycosylation sites and the PEG effect on receptor binding supported the previously reported structure-function relationship of rhTSH glycosylation. This long-acting rhTSH has the potential to significantly improve patient convenience and provider flexibility while reducing potential side effects associated with a sudden elevation of serum TSH.
Asunto(s)
Tirotropina/química , Tirotropina/farmacología , Animales , Carbohidratos/química , Femenino , Glicosilación , Semivida , Humanos , Masculino , Ratones , Ratones Endogámicos ICR , Modelos Moleculares , Polietilenglicoles/química , Ratas , Ratas Sprague-Dawley , Receptores de Tirotropina/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacología , Ácidos Siálicos/química , Tirotropina/análogos & derivados , Tirotropina/farmacocinéticaRESUMEN
BACKGROUND: When applying the recommended standard doses of recombinant human thyrotropin (rhTSH) in the diagnostic/therapeutic management of patients with differentiated thyroid cancer (DTC), the resulting peak TSH levels vary extensively. Previous studies applying multivariate statistics identified patient-inherent variables influencing the rhTSH/peak TSH relation. However, those results were inconclusive and partly conflicting. Notably, no independent role of renal function was substantiated, despite the fact that the kidneys are known to play a prominent role in TSH clearance from blood. Therefore, the study's aim was to investigate the impact of renal function on the peak TSH concentration after the standard administration of rhTSH used in the management of thyroid cancer. The second objective was to calculate a ranking regarding the effect sizes of the selected variables on the peak TSH. METHODS: There were 286 patients with DTC included in the study. Univariate and multivariate analyses were performed, testing the correlation of serum creatinine and glomerular filtration rate (GFR) as surrogate parameters of renal function, age, sex, weight, height, and body surface area (BSA) with the peak TSH level. In six additional patients, the subsequent TSH pharmacokinetics after the TSH peak were measured and qualitatively compared. RESULTS: By univariate analyses, TSH correlated negatively with BSA, GFR, weight, and height, and positively with age, female sex, and serum creatinine (p<0.001). On the multivariate analysis, the stepwise forward multiple linear regression revealed BSA and renal function as the two most influential independent variables, followed by age, sex, and height. The pharmacokinetic datasets indicated that these identified parameters also influence the TSH decline over time. CONCLUSION: Identifying those patients with a favorable combination of parameters predicting a high-peak TSH is the first step toward an individualization of rhTSH dosing. Additionally, the subsequent TSH decrease over time needs to be taken into account. A complete understanding of the interrelation of the identified key parameters and both the TSH peak and subsequent TSH pharmacokinetics might allow for a more personalized rhTSH dosage strategy to achieve sufficient TSH levels instead of the fixed dosing procedure used at present.
Asunto(s)
Riñón/fisiopatología , Insuficiencia Renal/fisiopatología , Tirotropina/farmacocinética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Superficie Corporal , Femenino , Humanos , Hipotiroidismo/diagnóstico , Hipotiroidismo/etiología , Riñón/efectos de los fármacos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Proteínas Recombinantes/sangre , Proteínas Recombinantes/farmacocinética , Análisis de Regresión , Insuficiencia Renal/sangre , Insuficiencia Renal/complicaciones , Estudios Retrospectivos , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/fisiopatología , Neoplasias de la Tiroides/complicaciones , Neoplasias de la Tiroides/fisiopatología , Neoplasias de la Tiroides/terapia , Tirotropina/sangre , Adulto JovenRESUMEN
Thyrotropin receptors are expressed in several extrathyroidal tissues including bone. We investigated whether the increase of thyroid-stimulating hormone (TSH) levels, under stable thyroid hormone levels, affects the bone markers. Thirty-two postmenopausal women, with papillary thyroid carcinoma, previously treated with near-total thyroidectomy and I131 remnant ablation underwent routine evaluation for residual disease by using injections of recombinant human TSH (rhTSH) without withdrawal from thyroxine therapy. Changes in TSH levels and various serum and urine markers of bone metabolism were followed before and 1, 2, 5, and 7 days after the rhTSH injections. A transient, significant decrease in serum calcium and urinary excretion of C- and N-terminal telopeptides of type I collagen was observed after the injections of rhTSH. Serum parathyroid hormone (PTH) started to rise along with TSH, but a significant increase of PTH was only reached on Day 5 when the TSH concentration had fallen more than 80% of the peak value. Bone alkaline phosphatase and osteocalcin did not show any significant change over time. There was no significant correlation between TSH concentration and the various parameters we measured. The study provides evidence that rhTSH produces a transient inhibition of bone resorption, as well as an attenuation of osteoblast response in spite of the PTH activation. Additional studies are needed to resolve the mechanisms by which TSH alters the response of the bone cells.
Asunto(s)
Remodelación Ósea/efectos de los fármacos , Tiroidectomía , Tirotropina/farmacología , Anciano , Biomarcadores/sangre , Biomarcadores/orina , Calcio/sangre , Calcio/orina , Carcinoma Papilar/radioterapia , Carcinoma Papilar/cirugía , Colágeno Tipo I/orina , Femenino , Humanos , Hipotiroidismo/tratamiento farmacológico , Persona de Mediana Edad , Neoplasia Residual/diagnóstico , Hormona Paratiroidea/sangre , Péptidos/orina , Fósforo/sangre , Fósforo/orina , Proteínas Recombinantes/farmacología , Neoplasias de la Tiroides/radioterapia , Neoplasias de la Tiroides/cirugía , Tirotropina/sangre , Tirotropina/farmacocinética , Tiroxina/uso terapéutico , Factores de TiempoRESUMEN
BACKGROUND: Two previously unreported thyrotropin (TSH) receptor mutations, A623F and I635V, were identified in toxic follicular thyroid adenoma specimens from two patients with hyperthyroidism. Our aim was to characterize both novel mutants in terms of the following: cAMP basal constitutive activity, cAMP response to TSH, plasma membrane expression levels, and TSH binding properties. METHODS: We performed DNA extraction for TSHR gene sequencing. COS-7 cells were transiently transfected with wild-type and mutated TSH receptor constructs for determination of basal cAMP constitutive activity and dose-response accumulation of cAMP using recombinant human TSH. Flow cytometry analysis was performed to evaluate plasma membrane expression. Binding studies using bovine TSH as a ligand were performed to compare the affinities of wild-type and mutated TSH receptors for TSH. RESULTS: Both mutants, A623F and I635V, had higher cAMP basal constitutive activities than the wild-type TSH receptor. A623F but not I635V showed lower plasma membrane expression than the wild-type receptor. IC50, an indirect measurement of ligand-receptor affinity, was lower in A623F and higher in I635V than in the wild-type TSH receptor, although no statistically significant differences were observed. No differences were observed in EC50 and although the absolute values of maximal stimulation achieved with both mutants were higher than the wild type, the differences did not achieve statistical significance. CONCLUSIONS: A623F and I635V are two naturally occurring TSH receptor mutations that increase basal cAMP accumulation and consequently promote the development of toxic follicular thyroid adenoma. cAMP response to increasing TSH dose is retained by A623F and I635V mutated receptors and the maximal stimulation obtained is not different from that of the wild-type receptor. Substitution of alanine 623 by phenylalanine 623 at the third intracellular loop of the TSH receptor decreases its plasma membrane expression, indicating that alanine 623 is important in directing the TSH receptor to the cell surface or in down-regulating the constitutive receptor. By contrast, isoleucine 635, located in the sixth transmembrane domain, is important in regulating TSH receptor basal activity but does not modify its plasma membrane expression.
Asunto(s)
Adenoma/genética , Hipertiroidismo/genética , Mutación/fisiología , Receptores de Tirotropina/genética , Neoplasias de la Tiroides/genética , Adenoma/patología , Adulto , Animales , Unión Competitiva , Células COS , Bovinos , Chlorocebus aethiops , AMP Cíclico/metabolismo , ADN/genética , Femenino , Citometría de Flujo , Humanos , Hipertiroidismo/etiología , Radioisótopos de Yodo , Persona de Mediana Edad , Mutación/genética , Receptores de Superficie Celular/genética , Receptores de Tirotropina/metabolismo , Neoplasias de la Tiroides/patología , Tirotropina/farmacocinéticaAsunto(s)
Radioisótopos de Yodo/uso terapéutico , Neoplasias Pulmonares/metabolismo , Radiofármacos/uso terapéutico , Neoplasias de la Tiroides/metabolismo , Tirotropina/uso terapéutico , Adulto , Femenino , Humanos , Radioisótopos de Yodo/farmacocinética , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/secundario , Cintigrafía , Radiofármacos/farmacocinética , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéutico , Hormonas Tiroideas/administración & dosificación , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/patología , Tirotropina/farmacocinética , Tomografía Computarizada por Rayos XRESUMEN
No disponible
No disponible
Asunto(s)
Humanos , Tirotropina/farmacocinética , Hipotiroidismo/tratamiento farmacológico , Neoplasias de la Tiroides/diagnóstico , Tiroidectomía , Neoplasias de la Tiroides/cirugía , Pruebas de Función de la TiroidesRESUMEN
This study investigated the thyroidal response to administration of recombinant human thyroid stimulating hormone (rhTSH) by means of serum total thyroxine (TT(4)) concentration and pertechnetate uptake by the thyroid gland in six healthy euthyroid spayed female cats. A pertechnetate scan was performed on day 1 to calculate thyroid/salivary gland (T/S) uptake ratio. On day 3, 25 microg rhTSH was injected intravenously. Six hours later the thyroid scan was repeated as on day 1. Blood was drawn for serum TT(4) measurement prior to injection of rhTSH and performance of the pertechnetate scan. Statistically significant differences in mean serum TT(4) concentration, T/S uptake ratio before and 6h after rhTSH administration and T/S uptake ratio between left and right lobes were noted. We can conclude that 25 microg rhTSH increases pertechnetate uptake in the thyroid glands of cats, this should be taken into account when thyroid scintigraphy after rhTSH administration is interpreted.
Asunto(s)
Gatos/sangre , Proteínas Recombinantes/farmacocinética , Pertecnetato de Sodio Tc 99m/farmacología , Glándula Tiroides/efectos de los fármacos , Tirotropina/farmacocinética , Tiroxina/sangre , Animales , Enfermedades de los Gatos/sangre , Enfermedades de los Gatos/diagnóstico , Femenino , Hipotiroidismo/sangre , Hipotiroidismo/diagnóstico , Hipotiroidismo/veterinaria , Cintigrafía/métodos , Cintigrafía/veterinaria , Proteínas Recombinantes/administración & dosificación , Glándula Tiroides/fisiología , Tirotropina/administración & dosificación , Factores de TiempoRESUMEN
CONTEXT: We have previously reported that the TSH receptor/cAMP cascade enhances the coordinate expression of the rate-limiting endocytic catalysts, Rab5a and Rab7, which respectively promote thyroglobulin (Tg) internalization and transfer to lysosomes, thereby accelerating thyroid hormone secretion. OBJECTIVE: We address whether TSH further controls Rab5a activity by promoting its GTP-bound state. DESIGN: We compared Rab5a activation in seven pairs of hyperactive and corresponding quiescent thyroid tissues; TSH effect was reproduced on polarized cultures of normal human thyrocytes. PATIENTS: We studied seven euthyroid patients bearing hyperactive autonomous adenomas; normal thyroid tissue for culture. MAIN OUTCOME MEASUREMENTS: Rab5a GDP/GTP exchange factor activity [Rab5a-guanine nucleotide exchange factor (GEF)], expression of Rabex-5 (a Rab5a-GEF), and function of thyrocytes in vitro were the main outcome measures. RESULTS: In autonomous adenomas, constitutive activation increased both total activity and sedimentability (membrane recruitment) of Rab5a-GEF, compared with perinodular tissues. Increased Rab5a-GEF activity correlated with increased expression of Rabex-5 and Rab5a, as well as with Tg store depletion. In polarized human thyrocyte monolayers, TSH did not affect total Rab5a-GEF activity after 2 h but promoted its membrane recruitment; after 4 d, TSH increased both Rab5a-GEF activity and Rabex-5 expression and recruitment onto membranes where Rabex-5 coimmunoprecipitated with Rabaptin-5 and Rab5a. Sedimentable Rab5a-GEF perfectly correlated with apical endocytosis and lysosomal transfer of 125I-Tg, and with basolateral secretion of 125I-derived hormones. CONCLUSION: This study provides the first clinical and experimental evidence that regulation of the activity of a rate-limiting endocytic catalyst finely tunes a tightly controlled cellular function that ultimately governs whole body metabolism.
Asunto(s)
Endocitosis/fisiología , Guanosina Trifosfato/metabolismo , Glándula Tiroides/metabolismo , Tirotropina/farmacocinética , Proteínas de Unión al GTP rab5/metabolismo , Polaridad Celular/fisiología , Células Cultivadas , Endocitosis/efectos de los fármacos , Factores de Intercambio de Guanina Nucleótido/metabolismo , Guanosina Difosfato/metabolismo , Humanos , Técnicas In Vitro , Radioisótopos de Yodo , Transporte de Proteínas/efectos de los fármacos , Transporte de Proteínas/fisiología , Fracciones Subcelulares/metabolismo , Glándula Tiroides/citologíaRESUMEN
No disponible
Asunto(s)
Humanos , Cintigrafía/métodos , Enfermedades de la Tiroides , Neoplasias de la Tiroides , ATPasa Intercambiadora de Sodio-Potasio/análisis , Tirotropina/farmacocinéticaRESUMEN
CONTEXT: A modern approach to congenital hypothyroidism requires a definitive diagnosis of the underlying mechanisms; this can be achieved within the first weeks of life. When uncertainty persists, treatment is commenced, and the definitive diagnosis of congenital hypothyroidism is deferred to the age of 3 yr. OBJECTIVES: The interruption of thyroid replacement treatment is perceived as risky by parents and physicians. The aim of this pilot study was to test the possibility of a definitive diagnosis during thyroid replacement treatment, using stimulation of thyroid tissue by recombinant human (rh)TSH. SUBJECTS: Eight patients, three boys and five girls, age 5-15 yr (mean, 9.5+/-3.7 yr), with congenital hypothyroidism that had been diagnosed by the neonatal screening program, and having their diagnosis verified between the ages of 3-4 yr, were reevaluated while on thyroid replacement therapy. INTERVENTIONS: Patients received im 0.6 mg/m2 rhTSH on two consecutive days. RESULTS: rhTSH pharmacokinetics, maximal concentration, t1/2, and area under the curve in children were different as compared with adults. In the patients with intact TSH receptors, free T4 levels decreased after the first and the second injection of rhTSH (P=0.0137 and P=0.0149, respectively). All eight children showed identical scintigraphy after rhTSH administration as compared with thyroid replacement withdrawal. CONCLUSIONS: The use of rhTSH is effective for definitive diagnosis of congenital hypothyroidism during thyroid replacement treatment, and no safety issues were encountered.
Asunto(s)
Hipotiroidismo/tratamiento farmacológico , Glándula Tiroides/anomalías , Tirotropina/uso terapéutico , Adolescente , Niño , Preescolar , Femenino , Humanos , Hipotiroidismo/clasificación , Masculino , Proteínas Recombinantes/uso terapéutico , Tirotropina/sangre , Tirotropina/farmacocinéticaAsunto(s)
Neoplasias de la Tiroides/tratamiento farmacológico , Tirotropina/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Hipotiroidismo/prevención & control , Radioisótopos de Yodo/sangre , Radioisótopos de Yodo/uso terapéutico , Masculino , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Radioterapia Adyuvante , Proteínas Recombinantes/uso terapéutico , Tiroglobulina/sangre , Hormonas Tiroideas/sangre , Neoplasias de la Tiroides/sangre , Neoplasias de la Tiroides/radioterapia , Tirotropina/economía , Tirotropina/farmacocinética , Imagen de Cuerpo EnteroRESUMEN
The properties of a human monoclonal antibody to the thyrotropin receptor (TSHR) (M22) with the characteristics of patient sera thyroid stimulating autoantibodies is described. Similar concentrations (pmol/L) of M22 Fab and porcine TSH had similar stimulating effects on cyclic adenosine monophosphate (cAMP) production in TSHR-transfected Chinese hamster ovary cells whereas higher doses of intact M22 immunoglobulin G (IgG) were required to cause the same level of stimulation. Patient sera containing TSHR autoantibodies with TSH antagonist (blocking) activity inhibited M22 Fab and IgG stimulation in a similar way to their ability to block TSH stimulation. Thyroid-stimulating monoclonal antibodies (TSmAbs) produced in mice inhibited 125I-TSH binding and 125I-M22 Fab binding to the TSHR but the mouse TSmAbs were less effective inhibitors than M22. These competition studies emphasized the close relationship between the binding sites on the TSHR for TSH, TSHR autoantibodies with TSH agonist activity, and TSHR autoantibodies with TSH antagonist activity. Recombinant M22 Fab could be produced in Escherichia coli and the recombinant and hybridoma produced Fabs were similarly active in terms of inhibition of TSH binding and cAMP stimulation. The crystal structure of M22 Fab was determined to 1.65 A resolution and is that of a standard Fab although the hypervariable region of the heavy chain protrudes further from the framework than the hypervariable region of the light chain. The M22 antigen binding site is rich in aromatic residues and its surface is dominated by acidic patches on one side and basic patches on the other in agreement with an important role for charge-charge interactions in the TSHR-autoantibody interaction.
Asunto(s)
Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/genética , Autoanticuerpos/química , Autoanticuerpos/genética , Receptores de Tirotropina/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Autoanticuerpos/inmunología , Células CHO , Clonación Molecular , Cricetinae , Cristalografía por Rayos X , Escherichia coli , Humanos , Fragmentos Fab de Inmunoglobulinas/química , Fragmentos Fab de Inmunoglobulinas/genética , Fragmentos Fab de Inmunoglobulinas/inmunología , Radioisótopos de Yodo , Pruebas de Neutralización , Estructura Terciaria de Proteína , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Relación Estructura-Actividad , Glándula Tiroides/inmunología , Tirotropina/farmacocinéticaRESUMEN
UNLABELLED: The follow-up of differentiated thyroid cancer (DTC) is currently performed by serum Tg levels determination and whole body scan (WBS) with 131I. In this regard, the latter represents the main tool to localize metastatic tissue, but is characterized by the induction of severe hypothyroidism. Moreover, WBS displays poor sensitivity in poorly differentiated tumors due to a loss of iodine uptake capacity. AIM: In this study we describe an alternative tracer, radiolabeled rhTSH, for the diagnosis of non-iodine uptaking DTC metastases. METHODS: rhTSH was iodinated with 125I or 123I using an enzymatic method with lactoperoxidase/glucose oxidase. In vitro stability of labeled compounds was assessed in saline and serum and in vivo studies were performed in tumor-bearing nude mice. Three mice were inoculated with ARO cells (TSH receptor negative) and three with PTC-1 cells (TSH receptor positive). After 25 days, mice were injected with 10 microg of 123I-rhTSH (100 microCi) and static images were acquired at 30 minutes, 1, 2, and 3 hours. Animals were then sacrificed and dissected for organ counting. RESULTS: RhTSH was radioiodinated to high specific activity: 132.2 mCi/mg for 123I-rhTSH, 94.3 for 125I-rhTSH. In vitro stability tests revealed no significant release of radioiodine. A clear tumor uptake was detectable after 2 hours in all animals implanted with PTC-1. CONCLUSION: Results obtained so far suggest that radiolabeled rhTSH might be a promising radiopharmaceutical for diagnosis and follow-up of DTC.
Asunto(s)
Radioisótopos de Yodo , Metástasis de la Neoplasia/diagnóstico , Radiofármacos , Proteínas Recombinantes , Neoplasias de la Tiroides/diagnóstico , Tirotropina , Animales , Línea Celular Tumoral , Humanos , Radioisótopos de Yodo/farmacocinética , Ratones , Ratones Desnudos , Metástasis de la Neoplasia/patología , Control de Calidad , Radiofármacos/química , Radiofármacos/aislamiento & purificación , Radiofármacos/farmacocinética , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/farmacocinética , Neoplasias de la Tiroides/tratamiento farmacológico , Neoplasias de la Tiroides/patología , Tirotropina/química , Tirotropina/aislamiento & purificación , Tirotropina/farmacocinética , Distribución Tisular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
AIM: Elevated iodine intake is a serious problem in the diagnostic and therapeutic application of (131)iodine in patients with differentiated thyroid cancer. Therefore, iodine avoidance is necessary 3 months in advance. Additionally, endogenous stimulation requires withdrawal of thyroid hormone substitution for 4 weeks. Exogenous stimulation using recombinant human TSH (rhTSH) enables the continuous substitution of levothyroxine, which contains 65.4% of its molecular weight in iodine. Thus, a substantial source of iodine intake is maintained during exogenous stimulation. Although this amount of stable iodine is comparable to the iodine intake in regions of normal iodine supply, it may reduce the accumulation of radioiodine in thyroid carcinoma tissue. The aim of this study was to assess the iodine excretion depending on different ways of stimulation. METHODS: Iodine excretion was measured in 146 patients in the long term follow up after differentiated thyroid carcinoma. Patients were separated into 2 groups, those on hormone withdrawal (G I) and rhTSH-stimulated patients on hormone substitution (G II). RESULTS: Iodine excretion was significantly lower in hypothyroid patients (G I, median 50 micro g/l, range: 25-600 micro g/l) than in those under levothyroxine medication (G II, median 75 micro g/l, 25-600 micro g/l, p <0.027). TSH in G I (median 57.0 micro U/ml, range: 14.4-183 micro U/ml) was significantly lower (p <0.001) than in G II (117 micro U/ml, 32.2-281 micro U/ml). CONCLUSION: Iodine excretion was higher in patients under rhTSH-stimulation than after hormone withdrawal. This may indicate an increased iodine pool in rhTSH-stimulated patients (deiodination of levothyroxine), thus limiting the sensitivity of radioiodine scanning to the level of endogenous stimulation despite significantly higher TSH levels during rhTSH-stimulation.
Asunto(s)
Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/radioterapia , Tirotropina , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/radioterapia , Carcinoma Papilar/diagnóstico por imagen , Carcinoma Papilar/radioterapia , Diagnóstico Diferencial , Femenino , Humanos , Radioisótopos de Yodo/orina , Masculino , Persona de Mediana Edad , Cintigrafía , Proteínas Recombinantes , Tirotropina/farmacocinética , Distribución TisularRESUMEN
OBJECTIVE: To report an attempt to shorten the preparation interval before radioactive iodine administration using plasmapheresis in a 77-year-old woman with a history of papillary thyroid carcinoma with local recurrence and lung metastases, in whom the administration of a high dose of radioactive iodine was intended as a desperate rescue procedure. METHODS: The patient was initially started on cholestyramine. Two days later, plasmapheresis was performed. RESULTS: Plasmapheresis rapidly decreased free tri-iodothyronine (FT(3)) and free thyroxine (FT(4)). Serum FT(4) subsequently remained low, while FT(3) recovered the next day. Thyroid-stimulating hormone (TSH) reached 25 mIU/l in 14 days, which is within the time frame required to reach the target TSH level by withdrawing levothyroxine alone. CONCLUSION: Plasmapheresis is very effective in eliminating thyroid hormones from the circulation. However, it does not seem to accelerate thyrotroph recovery to a considerable extent after prolonged suppression.